Literature DB >> 15050920

Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

Sergei Roumiantsev1, Daniela S Krause, Carola A Neumann, Christopher A Dimitri, Frances Asiedu, Nicholas C P Cross, Richard A Van Etten.   

Abstract

8p11 myeloproliferative syndrome (EMS) is a hematopoietic stem cell disorder characterized by myeloid hyperplasia and non-Hodgkin's lymphoma with chromosomal translocations fusing several genes, most commonly ZNF198, to fibroblast growth factor receptor-1 (FGFR1). However, patients with BCR-FGFR1 fusion present with typical chronic myeloid leukemia (CML). We demonstrate that ZNF198-FGFR1 induces EMS-like disease in mice, with myeloproliferation and T lymphoma arising from common multipotential progenitors. Mutation of FGFR1 Tyr766 attenuates both myeloid and lymphoid diseases, identifying phospholipase C-gamma1 as a downstream effector. Bcr-FGFR1 binds Grb2 via Bcr Tyr177 and induces CML-like leukemia in mice, whereas Bcr-FGFR1/Y177F lacks Grb2 binding and causes EMS-like disease. These results implicate different signaling pathways originating from both kinase and fusion partner in the pathogenesis of CML and EMS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050920     DOI: 10.1016/s1535-6108(04)00053-4

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  51 in total

1.  Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Authors:  Mingqiang Ren; Haiyan Qin; Ruizhe Ren; Josephine Tidwell; John K Cowell
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

2.  FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model.

Authors:  Haiyan Qin; Qing Wu; John K Cowell; Mingqiang Ren
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

3.  Growth factor receptors as regulators of hematopoiesis.

Authors:  Michael A Weinreich; Ingrid Lintmaer; Linlin Wang; H Denny Liggitt; Michael A Harkey; C Anthony Blau
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

Review 4.  GAB2--a scaffolding protein in cancer.

Authors:  Sarah J Adams; Iraz T Aydin; Julide T Celebi
Journal:  Mol Cancer Res       Date:  2012-08-07       Impact factor: 5.852

5.  Increasing alternative promoter repertories is positively associated with differential expression and disease susceptibility.

Authors:  Song Liu
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

Review 6.  Roles of FGFR in oral carcinogenesis.

Authors:  Xiaoyan Xie; Zhiyong Wang; Fangman Chen; Yao Yuan; Jiayi Wang; Rui Liu; Qianming Chen
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

Review 7.  The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?

Authors:  Sumera Rizvi; Mitesh J Borad
Journal:  J Gastrointest Oncol       Date:  2016-10

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  Function, regulation and pathological roles of the Gab/DOS docking proteins.

Authors:  Franziska U Wöhrle; Roger J Daly; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2009-09-08       Impact factor: 5.712

10.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.